Commentary/Editorials

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
Hui Yu, Ping Chen, Liangping Xia, Sha Fu, Chen Chen, Xuanye Zhang, Lina He, Bei Zhang, Yixin Zhou, Shaodong Hong

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e003431; DOI: 10.1136/jitc-2021-003431
Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups
David Hsiehchen, Magdalena Espinoza, Cristina Valero, Chul Ahn, Luc G T Morris

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e003683; DOI: 10.1136/jitc-2021-003683
Moving beyond conventional stratified analysis to assess the treatment effect in a comparative oncology study
Ryan Sun, Zachary McCaw, Lu Tian, Hajime Uno, Fangxin Hong, Dae Hyun Kim, Lee-Jen Wei

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e003323; DOI: 10.1136/jitc-2021-003323
Letter to the editor from Pant et al
Shubham Pant, Justin T Moyers, Aung Naing

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e003991; DOI: 10.1136/jitc-2021-003991
Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology
Berna C Özdemir

Journal for ImmunoTherapy of Cancer Feb 2021, 9 (2) e002220; DOI: 10.1136/jitc-2020-002220
Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver?
Yana G Najjar

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002820; DOI: 10.1136/jitc-2021-002820
Letter to the editor: radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers
Mateus Trinconi Cunha, Vinicius Jardim Carvalho, Rafael Maffei Loureiro, Carlos Eduardo Brantis-de-Carvalho, Murilo Bicudo Cintra, Gilberto de Castro Junior

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e003044; DOI: 10.1136/jitc-2021-003044
Author response to Cunha et al
Rivka R Colen, Christian Rolfo, Murat Ak, Mira Ayoub, Sara Ahmed, Nabil Elshafeey, Priyadarshini Mamindla, Pascal O Zinn, Chaan Ng, Raghu Vikram, Spyridon Bakas, Christine B Peterson, Jordi Rodon Ahnert, Vivek Subbiah, Daniel D Karp, Bettzy Stephen, Joud Hajjar, Aung Naing

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e003299; DOI: 10.1136/jitc-2021-003299
Do the benefits of being a smoker hint at the existence of PD-1/PD-L1 sensitizers for patients on single-agent immunotherapy?
Gintaras Zaleskis, Vita Pasukoniene, Dainius Characiejus, Vincas Urbonas

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e003191; DOI: 10.1136/jitc-2021-003191
Not all hematopoietic growth factors are created equal: should we gain information for their use with immunotherapy?
Paolo Bossi, Cristina Gurizzan, Luigi Lorini, Pierluigi di Mauro, Chiara Sardini, Marco Merlano

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e003154; DOI: 10.1136/jitc-2021-003154

Main menu

Commentary/Editorials

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Commentary/Editorials

Pages